Ipsogen Announces 3 Studies At ASCO Meeting Extending The Utility Of The Genomic Grade Index For Predicting Response To Chemotherapy In Breast Cancer
May 22nd 2008Drug InformationBreast Cancer
IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will present the results of two studies on the Genomic Grade index (GGi) at the ASCO Annual Meeting, held in Chicago from May 30 to June 3, 2008. The data indicate that the Genomic Grade index predicts response to chemotherapy in breast cancer.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
